Kurin, Inc., a leader in innovative blood culture collection technology designed to reduce contamination and improve patient outcomes, announced today that the United States Court of Appeals for the Federal Circuit has ruled in Kurin’s favor in a patent dispute brought by Magnolia Medical Technologies accusing Kurin’s Lock of infringement. The U. S. District Court had previously ruled in Kurin’s favor and the appellate court affirmed the district court’s judgment of non-infringement.
“Although we expected this ruling, it is gratifying to see another Court validate our position that Kurin Lock does not infringe Magnolia patents, as they had claimed. This ruling affirms the strength and independence of Kurin’s technology,” said Bob Rogers, Chairman of the Board and CEO of Kurin, Inc. “We have always been confident in the innovation behind Kurin Blood Culture Collection Sets and their ability to help clinicians reduce blood culture contamination. Our focus remains on advancing solutions that improve patient care while helping hospitals—already facing significant resource constraints—reduce unnecessary costs.”
Blood culture contamination is a well-recognized challenge in healthcare that can lead to false-positive results, unnecessary treatments, and increased healthcare costs. Kurin’s solution addresses this problem by sidelining the initial portion of a blood draw that is most likely to contain skin contaminants, helping clinicians obtain more accurate diagnostic samples.
Kurin will continue to focus on innovation, clinical impact, and supporting healthcare providers with solutions that improve diagnostic accuracy and patient outcomes.
About Kurin, Inc.
Kurin® is a privately held, certified minority-owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption, and corporate acquisition of CUROS™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales, and service to tackle the persistent and costly fallout of false positive blood cultures. With agile development capabilities and intense customer focus, the Kurin Blood Collection Systems have quickly gained caregiver acceptance, have been proven to sideline skin contaminants during blood culture collection, and are the market-leading solution for blood culture collection best practice.
CUROS™ is a registered trademark of Solventum and Kurin has no connection to Solventum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311264098/en/